Sign Up to like & get recommendations! 0
Published in 2018 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2018.3242
Abstract: Key Points Question What are the optimal factors to use for constructing a nomogram to assess the probability of survival in patients with bone metastases arising from lung cancer? Findings This prognostic study of 477… read more here.
Sign Up to like & get recommendations! 0
Published in 2020 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2020.13565
Abstract: Key Points Question Is targeted gene testing cost-effective in patients with metastatic gastrointestinal stromal tumor? Findings This economic evaluation developed a Markov model to examine the cost-effectiveness of targeted gene testing with tailored imatinib dosing… read more here.
Sign Up to like & get recommendations! 1
Published in 2022 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2022.12347
Abstract: Key Points Question Is cytoreductive nephrectomy associated with improved overall survival for patients with metastatic clear cell renal cell carcinoma? Findings In this cohort study of 12 766 patients, receipt of a cytoreductive nephrectomy was not… read more here.
Sign Up to like & get recommendations! 1
Published in 2022 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2022.21626
Abstract: Key Points Question Is there an association among allostatic load (AL), social determinants of health (SDHs), and overall mortality in patients with metastatic non–small cell lung cancer (NSCLC)? Findings In this cross-sectional study of 143… read more here.
Sign Up to like & get recommendations! 2
Published in 2022 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2022.25459
Abstract: Key Points Question Following the US Food and Drug Administration’s approval of PD-1 immune checkpoint inhibitors (ICI) for metastatic melanoma, what were the utilization and overall survival associated with ICI in the first-line setting after… read more here.
Sign Up to like & get recommendations! 2
Published in 2023 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2022.52244
Abstract: This comparative effectiveness research study compares outcomes of first-line therapy with immune checkpoint inhibitors vs chemotherapy among patients who have metastatic colorectal cancer with high microsatellite instability, mismatch repair deficiency, and/or high tumor mutational burden. read more here.
Sign Up to like & get recommendations! 2
Published in 2023 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2023.4254
Abstract: Key Points Question Is antibiotic therapy associated with response to chemotherapy in patients with metastatic pancreatic ductal adenocarcinoma (PDAC)? Findings In this cohort study of 3850 older adults with metastatic PDAC, receipt of perichemotherapy antibiotics… read more here.
Sign Up to like & get recommendations! 2
Published in 2023 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2023.7444
Abstract: This cohort study uses published clinical trial data to assess long-term survival of patients with metastatic urothelial carcinoma who are treated with immune checkpoint inhibitors. read more here.
Sign Up to like & get recommendations! 1
Published in 2022 at "JAMA Oncology"
DOI: 10.1001/jamaoncol.2022.5959
Abstract: This nonrandomized controlled trial evaluates the clinical benefits and safety of atezolizumab plus bevacizumab for treatment of patients with metastatic non–small cell lung cancer (NSCLC) with high tumor mutation burden. read more here.
Sign Up to like & get recommendations! 1
Published in 2021 at "Cancer Medicine"
DOI: 10.1002/cam4.4446
Abstract: Arginine depletion interferes with pyrimidine metabolism and DNA damage repair pathways. Preclinical data demonstrated that depletion of arginine by PEGylated arginine deiminase (ADI‐PEG 20) enhanced liposomal doxorubicin (PLD) cytotoxicity in cancer cells with argininosuccinate synthase… read more here.
Sign Up to like & get recommendations! 1
Published in 2023 at "Cancer medicine"
DOI: 10.1002/cam4.5885
Abstract: Little is known about the heterogeneous nature of financial hardship in younger patients with metastatic disease and the extent to which insurance protects against it. We examine the association between insurance status and multidimensional indicators… read more here.